Table 1.
Clinicopathological characteristics of the alternative polyadenylation (APA) subtypes of TNBC
| Characteristics | Number of patients (%) | FUSCC APA subtypes | p-value | |||
|---|---|---|---|---|---|---|
| LAR | MLIA | BL | S | |||
| n (%) | n (%) | n (%) | n (%) | |||
| Total | 165 | 36 | 36 | 67 | 26 | |
| Age | 0.001 | |||||
| ≤ 50 years | 68 (41.2) | 7 (19.4) | 10 (27.8) | 38 (56.7) | 13 (50.0) | |
| > 50 years | 97 (58.8) | 29 (80.6) | 26 (72.2) | 29 (43.3) | 13 (50.0) | |
| Menopausal status | 0.006 | |||||
| Premenopause | 64 (38.8) | 7 (19.4) | 12 (33.3) | 36 (53.7) | 9 (34.6) | |
| Postmenopause | 101 (61.2) | 29 (80.6) | 24 (66.7) | 31 (46.3) | 17 (65.4) | |
| Tumor size | 0.370 | |||||
| ≤ 2 cm | 58 (35.2) | 14 (38.9) | 12 (33.3) | 21 (31.3) | 11 (42.3) | |
| > 2 cm | 104 (63.0) | 22 (61.1) | 24 (66.7) | 45 (67.2) | 13 (50.0) | |
| Unknown | 3 (1.8) | 0 (0.0) | 0 (0.0) | 1 (1.5) | 2 (7.7) | |
| Lymph node | 0.336 | |||||
| Negative | 86 (52.1) | 14 (38.9) | 19 (52.8) | 38 (56.7) | 15 (57.7) | |
| Positive | 79 (47.9) | 22 (61.1) | 17 (47.2) | 29 (43.3) | 11 (42.3) | |
| Grade | 0.071 | |||||
| I-II | 32 (19.4) | 12 (33.3) | 9 (25.0) | 10 (14.9) | 1 (3.8) | |
| III | 104 (63.0) | 20 (55.6) | 19 (52.8) | 46 (68.7) | 19 (73.1) | |
| Unknown | 29 (17.6) | 4 (11.1) | 8 (22.2) | 11 (16.4) | 6 (23.1) | |
| Ki-67 | 0.042 | |||||
| < 30% | 32 (19.4) | 12 (33.3) | 8 (22.2) | 10 (14.9) | 2 (7.7) | |
| ≥ 30% | 132 (80.0) | 23 (63.9) | 28 (77.8) | 57 (85.1) | 24 (92.3) | |
| Unknown | 1 (0.6) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Neurovascular invasion | 0.551 | |||||
| Negative | 70 (42.4) | 13 (36.1) | 13 (36.1) | 32 (47.8) | 12 (46.2) | |
| Positive | 95 (57.6) | 23 (63.9) | 23 (63.9) | 35 (52.2) | 14 (53.8) | |
| EGFR | 0.067 | |||||
| Negative | 107 (64.8) | 17 (47.2) | 24 (66.7) | 49 (73.1) | 17 (65.4) | |
| Positive | 54 (32.7) | 18 (50.0) | 12 (33.3) | 17 (25.4) | 7 (26.9) | |
| Unknown | 4 (2.4) | 1 (2.8) | 0 (0.0) | 1 (1.5) | 2 (7.7) | |
| CK5/6 | 0.002 | |||||
| Negative | 72 (43.6) | 20 (55.6) | 20 (55.6) | 28 (41.8) | 4 (15.4) | |
| Positive | 90 (54.5) | 15 (41.7) | 16 (44.4) | 39 (58.2) | 20 (76.9) | |
| Unknown | 3 (1.8) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 2 (7.7) | |
| CK14 | <0.001 | |||||
| Negative | 94 (57.0) | 31 (86.1) | 26 (72.2) | 29 (43.3) | 8 (30.8) | |
| Positive | 68 (41.2) | 4 (11.1) | 10 (27.8) | 38 (56.7) | 16 (61.5) | |
| Unknown | 3 (1.8) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 2 (7.7) | |
Abbrevations: BL: basal-like; CK: cytokeratin; EGFR: epidermal growth factor receptor; LAR: luminal androgen receptor; MLIA: mesenchymal-like immune-activated; S: suppressed.